Treatment of Hodgkin's Disease: A Twenty-Year Follow-up of Patients at a Center in Korea.
10.3349/ymj.2006.47.4.455
- Author:
June Won CHEONG
1
;
Soo Young PARK
;
Jae Kyung ROH
;
Chang Ok SUH
;
Jee Sook HAHN
Author Information
1. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. medi@yumc.yonsei.ac.kr
- Publication Type:Original Article
- Keywords:
Hodgkin's disease;
twenty year survival;
chemotherapy;
Korea
- MeSH:
Treatment Outcome;
Remission Induction;
Prognosis;
Middle Aged;
Male;
Korea;
Humans;
Hodgkin Disease/mortality/*therapy;
Follow-Up Studies;
Female;
Disease-Free Survival;
Child, Preschool;
Child;
Antineoplastic Agents/*pharmacology;
Aged, 80 and over;
Aged;
Adult;
Adolescent
- From:Yonsei Medical Journal
2006;47(4):455-465
- CountryRepublic of Korea
- Language:English
-
Abstract:
Hodgkin's disease (HD) is a hematologic malignancy which shows common features regardless of race, but racial differences may be considered with certain clinical characteritcs. HD in Korea shows somewhat different characteristics when compared to cases in Western countries. We evaluated the clinical and histopathologic characteristics of HD, the outcomes of various chemotherapy regimens, and prognostic factors of HD in Korea. One hundred and five patients with initial histopathologic diagnosis of Hodgkin's disease were retrospectively reviewed 20 years after diagnosis at Yonsei University College of Medicine. Nodular sclerosis was the most common histopathogic subtype (41%) and mixed cellularity was nearly as common (40%). The overall complete remission rate (CR) was 87.6%. The disease-free survival (DFS) and overall survival (OS) rate were 79.2% and 84.8% at 5-years, 70% and 79.2% at 10- and 20-years. There were no significant differences in CR rate and DFS, but OS rates were significantly higher in m-BACOP and ABVD regimen. Univariate analysis revealed that age, B-symptom, ECOG scale, Ann Arbor stage, international prognostic index, and serum beta2-microglobulin level were significant prognostic factors for both DFS and OS. Multivariate analysis demonstrated that age, B symptoms, and ECOG scale were significant prognostic factors for OS only. In conclusion, the survival rates of HD patients in our center were superior to those of previous reports in Korea and Western countries. Considering the higher OS rate and decreased incidence of side effects, the ABVD regimen may be recommended for the initial treatment of Hodgkin's disease.
